Drug diversion is a national crisis affecting public health and social and economic welfare. Drug diversion activities not only cause potential harm to patients and healthcare professionals, but also to the organizations that employ them – causing healthcare organizations to face legal, financial, operational and reputational risks and regulatory fines. Now consider that about 15% of all healthcare workers will misuse drugs or alcohol at some point in their career. To effectively address these issues and mitigate risks, healthcare organizations must have a comprehensive interdisciplinary drug diversion management program that include rigorous controls and monitoring.
In partnership with the Association for Healthcare Internal Auditors (AHIA), Baker Tilly specialists present this webinar reviewing the common points of risk, and how to develop a comprehensive risk-based internal audit approach for drug diversion remediation and ongoing monitoring.
After attending this webinar, participants will be able to:
Acute care facilities and academic medical centers. Directors of compliance, CEOs, COOs, CFOs.